Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Sherry Winter

Sherry Winter

Senior Solution Marketing Manager

Connect with Sherry Winter on LinkedIn
Website:

About the author:

As a Senior Solution Marketing Manager at Elsevier, Sherry is responsible for delivering insights on markets and customers, messaging, positioning and thought leadership for life science solutions, including PharmaPendium, that enable Drug Discovery and Development and Pharmacovigilance.

Sherry has a PhD in Medical Genetics from the University of Toronto, Canada and has several years of experience in life science marketing and communications, having worked at QIAGEN in Hilden, Germany before joining Elsevier and also in Research Communications at the University Health Network in Toronto, Canada. Prior to this, Sherry performed research at cancer institutes in both Canada and the US.


Posts by Sherry Winter

Doing our part to improve drug safety

Posted on October 2nd, 2018 in Pharma R&D

Pharmacovigilance and drug safety teams are never short of work. There’s a vast amount of peer-reviewed literature to sift through for adverse event information. Over 800,000 pharmacology and biomedicine articles Continue reading “Doing our part to improve drug safety” »

Translational Medicine, Data Access and Pharmaceutical Innovation

Posted on January 17th, 2018 in Pharma R&D

Some of the early seeds of translational medicine were planted in 1992 when the U.S. National Cancer Institute introduced a program designed to improve and accelerate the knowledge exchange between basic and clinical science. Continue reading “Translational Medicine, Data Access and Pharmaceutical Innovation” »

Extreme Makeover: Clinical Trials Edition

Posted on December 4th, 2017 in Pharma R&D

In a piece featured in the PharmaTimes, Katrina Megget points out the sad state of affairs when it comes to clinical trials, highlighting some appalling stats on the frequent failure to reach enrollment targets (in some cases, not finding any patients at all) and the tendency for studies to go on far longer than anticipated. Continue reading “Extreme Makeover: Clinical Trials Edition” »

Why a reliable FAERS searching capability is essential for pharma companies

Posted on October 27th, 2017 in Pharmacovigilance

In the description of the FDA Adverse Event Reporting System (FAERS), the agency states that “voluntary and mandatory reporting plays an important role in the FDA’s post-market safety monitoring.” Continue reading “Why a reliable FAERS searching capability is essential for pharma companies” »

  1. 1
  2. 2
  3. 3